Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. SK Biopharmaceuticals Co., Ltd.
  6. Summary
    A326030   KR7326030004

SK BIOPHARMACEUTICALS CO., LTD.

(A326030)
  Report
End-of-day quote Korea Stock Exchange  -  2022-09-29
56900.00 KRW   -2.23%
07/14SK Biopharmaceuticals, Co., Ltd., Eurofarma Enters into Licensing Agreement for Cenobamate in Latin America
CI
07/14SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America
AQ
07/13SK Biopharmaceuticals 2022 Sustainability Report Reinforces its commitment to ESG Management
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
58700 58200 57000 58200 56900 Last
148178 109686 138754 124055 105068 Volume
-1.68% -0.85% -2.06% +2.11% -2.23% Change
Estimated financial data (e)
Sales 2022 232 B 0,16 B 0,16 B
Net income 2022 -111 B -0,08 B -0,08 B
Net cash position 2022 137 B 0,10 B 0,10 B
P/E ratio 2022 -40,3x
Yield 2022 -
Sales 2023 372 B 0,26 B 0,26 B
Net income 2023 -20,1 B -0,01 B -0,01 B
Net cash position 2023 104 B 0,07 B 0,07 B
P/E ratio 2023 -1 827x
Yield 2023 -
Capitalization 4 456 B 3 103 M 3 103 M
EV / Sales 2022 18,6x
EV / Sales 2023 11,7x
Nbr of Employees 254
Free-Float 35,7%
More Financials
Company
SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business. 
Sector
Pharmaceuticals
Calendar
11/17Earnings Release
More about the company
Ratings of SK Biopharmaceuticals Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about SK BIOPHARMACEUTICALS CO., LTD.
07/14SK Biopharmaceuticals, Co., Ltd., Eurofarma Enters into Licensing Agreement for Cenobam..
CI
07/14SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin..
AQ
07/13SK Biopharmaceuticals 2022 Sustainability Report Reinforces its commitment to ESG Manag..
AQ
05/13SK Biopharmaceuticals Swings to Loss in Q1
MT
04/19SK Inc. - Biopharm Investment and Sister Company Sign Collaborations to Advance Promisi..
AQ
03/28Axsome Therapeutics to Buy Sunosi From Jazz Pharmaceuticals
DJ
02/24SK Biopharmaceuticals Becomes First Korean Company to Join PSCI
AQ
02/08SK Biopharmaceuticals Reports 2021 Financial Results
AQ
01/04BIORCHESTRA and SK Biopharmaceuticals Collaborate to Develop Mirna-Targeted Therapeutic..
CI
2021Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPR..
AQ
2021Health Care Stocks Advance Premarket Thursday
MT
2021Endo International Signs Agreement to Commercialize SK Biopharmaceuticals' Cenobamate i..
MT
2021Cala Health, Inc. announced that it has received $77 million in funding from Ascension ..
CI
2021SK Biopharmaceuticals Narrows Loss in Q3
MT
2021Cala Health, Inc. announced that it expects to receive $49.999999 million in funding
CI
More news
News in other languages on SK BIOPHARMACEUTICALS CO., LTD.
07/14SK Biopharmaceuticals, Co., Ltd. et Eurofarma concluent un accord de licence pour le cé..
05/13SK Biopharmaceuticals subit une perte au premier trimestre
01/04BIORCHESTRA et SK Biopharmaceuticals collaborent pour développer des thérapies ciblant ..
2021Les actions du secteur de la santé progressent jeudi avant le marché
2021Endo International signe un accord pour commercialiser le cénobamate de SK Biopharmaceu..
More news
ETFs positioned on SK BIOPHARMACEUTICALS CO., LTD.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
KraneShares Emerging Market Healthcare Inde...0.93%1.67%NC
Invesco MSCI Emerging Markets ESG Climate P...0.57%-3.14%-NC
Xtrackers MSCI Korea 1C - USD0.26%-5.05%-NC
IShares MSCI Korea (Acc) - USD0.25%-5.14%-Korea
IShares MSCI Korea (Dist) - USD0.25%-5.16%-Korea
More ETFs positioned on SK BIOPHARMACEUTICALS CO., LTD.
Chart SK BIOPHARMACEUTICALS CO., LTD.
Duration : Period :
SK Biopharmaceuticals Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SK BIOPHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 56 900,00 KRW
Average target price 102 222,22 KRW
Spread / Average Target 79,7%
EPS Revisions
Managers and Directors
Jeong-Woo Cho President, Chief Executive Officer & Director
Young-Ju Bang Independent Director
Hae-Young Ahn Independent Director
Min-Seop Song Independent Director
Geun-Joo Hwang Non-Executive Director
Sector and Competitors